KAMADA LTD (KMDA) research
KAMADA LTD- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Last price
- $8.31
- As of
KAMADA LTD (KMDA): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 6-K filed 2026-09-17.
As of . Source: SEC EDGAR filings for KMDA. Method and limitations.
Share the KMDA intelligence card
See the full KMDA dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for KMDA on one page. Preview it with sample data, then open it live with a free account.
Preview the KMDA dossierActive signals for KMDA
- highINSTITUTIONAL_EXIT
CITADEL ADVISORS LLC cut 78% of KMDA (2026Q2)
- mediumEARNINGS_BEAT
Q2-2026: Beat consensus by 39.4%, EPS $0.16 vs $0.1148 estimate
- highINSTITUTIONAL_EXIT
MILLENNIUM MANAGEMENT LLC cut 70% of KMDA (2026Q1)
- mediumEARNINGS_BEAT
Q2-2025: Beat consensus by 45.6% - EPS $0.13 vs $0.0893 estimate
- mediumEARNINGS_MISS
Q4-2025: Missed consensus by 24.1% - EPS $0.06 vs $0.0791 estimate
FREE, NO ACCOUNT
Every signal on KMDA, as it fires
You are seeing 5 of 6 signals recorded on KMDA since 2026-05-24.
The five above landed across 4 days. The other 1 were recorded on those same days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in KMDA (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLCCUSIP M6240T109 · 2026Q2 | $5.4M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP M6240T109 · 2026Q2 | $1.1M | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP M6240T109 · 2026Q2 | $214K | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP M6240T109 · 2026Q2 | $106K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, KMDA
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
- 6-KSEC EDGAR ↗
KMDA against its peers
KMDA's operating margin of 14.5% ranks in the 86th percentile of 17 Drug Manufacturers - Specialty & Generic sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-05-31.
| Metric | KMDA | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 180M USD | 248M USD | 44 | 16 |
| Revenue YoY | 12.1% | n/a | n/a | 1 |
| Gross margin | 42.3% | 49.5% | 25 | 13 |
| Operating margin | 14.5% | -6.9% | 86 | 17 |
| Net margin | 11.2% | -18.7% | 92 | 17 |
| Return on equity | 7.5% | -22.2% | 91 | 15 |
Peers (19): TKNO, EOLS, VREOF, VRNO, NIKA, TLRY, AQST, CGC, ELTP, AKBA, CRLBF, HROW, DERM, CRON, CRDL, TSNDF, ADCT, ETON, GTBIF. Left out: EVO (period gap), BORAY (no annual filing), LFCR (no annual filing), PHBI (period gap), ASRT (no annual filing), OGI (period gap). Fiscal periods ending between 2025-12-31 and 2026-05-31. Every figure is one full fiscal year read from one annual filing (KMDA: 20-F), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more KMDA signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to KMDAand get the insider, 13F, options, and confluence read in one view.